When B cells break bad: development of pathogenic B cells in Sjogren's syndrome

Date

2020

Authors

Reed, J.H.
Verstappen, G.M.
Rischmueller, M.
Bryant, V.L.

Editors

Advisors

Journal Title

Journal ISSN

Volume Title

Type:

Journal article

Citation

Clinical and Experimental Rheumatology, 2020; 38(Suppl. 26):S-271-S-282

Statement of Responsibility

J.H. Reed, G.M. Verstappen, M. Rischmueller, V.L. Bryant

Conference Name

Abstract

Primary Sjögren’s syndrome (pSS) is often considered a B cell-mediated disease, yet the precise role of B cells in the pathogenesis is not fully understood. This is exemplified by the failure of multiple clinical trials directed at B cell depletion or inhibition. To date, most prognostic markers for severe disease outcomes are autoantibodies, but the underlying mechanisms by which B cells drive diverse disease presentations in pSS likely extend beyond autoantibody production. Here we outline an expanded role of B cells in disease pathogenesis drawing on examples from animal models of SS, and from other autoimmune diseases that share similar clinical or immunological abnormalities. We focus on recent findings from the detailed analysis of pathogenic B cells in patients with pSS to propose strategies for patient stratification to improve clinical trial outcomes. We conclude that an integrated cellular, molecular and genetic analysis of patients with pSS will reveal the underlying pathogenic mechanisms and guide precision medicine.

School/Discipline

Dissertation Note

Provenance

Description

Access Status

Rights

© Copyright Clinical and Experimental Rheumatology 2020.

License

Call number

Persistent link to this record